Purpose: We investigated associations between athletes’ use of sport supplements and their responsiveness to placebo and nocebo interventions. Methods: Participants (n=627) reported their intention to use, and actual use of, sport supplements. They then completed a 5x20m repeat sprint protocol in the baseline condition, prior to being randomized to one of three treatments. Participants in the positive-belief treatment were administered an inert capsule described as a potent supplement which would improve sprint performance. Participants in the negative-belief treatment were administered an inert capsule described as a potent supplement which would negatively affect sprint performance. Participants in the control treatment received neither instruction nor capsule. 20 minutes following baseline trials, all participants completed the same repeat sprint protocol in the experimental condition. Results: Compared to controls, no mean differences in performance were observed between baseline and experimental conditions for the positive-belief treatment (-0.07 ± 0.27%, d=0.02), but mean differences were observed for the negative-belief treatment (-0.92 ± 0.31%, d=0.32), suggesting a moderate nocebo effect. In the positive-belief treatment however, a relationship between intention to use supplements and performance was observed. Performance worsened by -1.10% ± 0.30% compared to baseline for participants not intending to use supplements, worsened by -0.64 ± 0.43% among those undecided about supplement use, but improved by 0.19 ± 0.24% among those participants intending to use supplements. Conclusion: Information about a harmful supplement worsened repeat sprint performance (a mean nocebo effect), whereas information about a beneficial supplement did not improve performance (no mean placebo effect was observed). However, participants’ intention to use sport supplements influenced the direction and magnitude of subsequent placebo responses, with participants intending to use supplements more likely to respond to the positive intervention.
1. American Psychological Association. Ethical principles of psychologists and code of conduct. Amer Psychol. 2010;57(12):1060-73.
2. Atlas LY, Wager TD. A meta-analysis of brain mechanisms of placebo analgesia: consistent findings and unanswered questions. Handb Exp Pharmacol. 2014;225:37-69.
3. Beedie CJ. Placebo effects in competitive sport: qualitative data. J Sports Sci Med. 2007;6(1):21-8.
4. Beedie CJ. All in the mind? Pain, placebo effect, and ergogenic effect of caffeine in sports performance. Open Access J Sports Med. 2010;1:87-94.
5. Beedie CJ, Coleman DA, Foad AJ. Positive and negative placebo effects resulting from the deceptive administration of an ergogenic aid. Int J Sport Nutr Exerc Metab. 2007;17(3):259-69.
6. Beedie CJ, Foad AJ. The placebo effect in sports performance: a brief review. Sports Med. 2009;39(4):313-29.
7. Beedie CJ, Foad AJ, Coleman DA. Identification of placebo responsive participants in 40km laboratory cycling performance. J Sports Sci Med. 2008;7(1):166-75.
8. Beedie CJ, Stuart EM, Coleman DA, Foad AJ. Placebo effects of caffeine on cycling performance. Med Sci Sports Exerc. 2006;38(12):2159-64.
9. Benedetti F, Amanzio M, Rosato R, Blanchard C. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat Med. 2011;17(10):1228-30.
10. Carlino E, Benedetti F. Different contexts, different pains, different experiences. Neuroscience. 2016;338:19-26.
11. Carlino E, Piedimonte A, Benedetti F. Nature of the placebo and nocebo effect in relation to functional neurologic disorders. Handb Clin Neurol. 2017;139:597-606.
12. Clark VR, Hopkins WG, Hawley JA, Burke LM. Placebo effect of carbohydrate feedings during a 40-km cycling time trial. Med Sci Sports Exerc. 2000;32(9):1642-7.
13. Cohen J. A power primer. Psychol Bull. 1992;112(1):155.
14. Cross MR, Brughelli M, Brown SR et al. Mechanical properties of sprinting in elite Rugby union and Rugby league. Int J Sports Physiol Perform. 2015;10(6):695-702.
15. Ferreira TN, Sabino-Carvalho JL, Lopes TR et al. Ischemic preconditioning and repeated sprint swimming: A placebo and nocebo study. Med Sci Sports Exerc. 2016;48(10):1967-75.
16. Foad AJ, Beedie CJ, Coleman DA. Pharmacological and psychological effects of caffeine ingestion in 40-km cycling performance. Med Sci Sports Exerc. 2008;40(1):158-65.
17. Goulet C, Valois P, Buist A, Cote M. Predictors of the use of performance-enhancing substances by young athletes. Clin J Sport Med. 2010;20(4):243-8.
18. Hall KT, Lembo AJ, Kirsch I et al. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One. 2012;7(10):e48135.
19. Hall KT, Loscalzo J, Kaptchuk TJ. Genetics and the placebo effect: the placebome. Trends Mol Med. 2015;21(5):285-94.
20. Haugen T, Buchheit M. Sprint running performance monitoring: Methodological and practical considerations. Sports Med. 2016;46(5):641-56.
21. Hopker JG, Foad AJ, Beedie CJ, Coleman DA, Leach G. Placebo effect of an inert gel on experimentally induced leg muscle pain. Open access journal of sports medicine. 2010;1:215-21.
22. Hopkins WG. Speadsheets for Analysis of Validity and Reliability. Sportsci. 2015;19:26-42.
23. Hopkins WG. Estimating sample size for magnitude-based inferences. Sportsci. 2016;10:63-9.
24. Hopkins WG, Hawley JA, Burke LM. Design and analysis of research on sport performance enhancement. Med Sci Sports Exerc. 1999;31(3):472-85.
25. Hrobjartsson A, Kaptchuk TJ, Miller FG. Placebo effect studies are susceptible to response bias and to other types of biases. J Clin Epidemiol. 2011;64(11):1223-9.
26. Hurst P, Foad AJ, Coleman DA, Beedie CJ. Development and validation of the Sports Supplements Beliefs Scale Perform Enhanc Health. In press.
27. Judd CM, McClelland GH, Ryan CS. Data analysis: A model comparison approach. Routledge; 2011, 295 p.
28. Kam-Hansen S, Jakubowski M, Kelley JM et al. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Transl Med. 2014;6(218):218ra5.
29. Klinger R, Colloca L, Bingel U, Flor H. Placebo analgesia: clinical applications. Pain. 2014;155(6):1055-8.
30. Leys C, Ley C, Klein O, Bernard P, Licata L. Detecting outliers: Do not use standard deviation around the mean, use absolute deviation around the median. Journal of Experimental Social Psychology. 2013;49(4):764-6.
31. Maganaris C, Collins D, M S. Expectancy Effects and Strength Training: Do Steroids Make a Difference? The Sport Psychologist. 2000;14:272–78.
32. McClung M, Collins D. “Because I know it will!”: placebo effects of an ergogenic aid on athletic performance. Journal of Sport and Exercise Psychology. 2007;29(3):382-94.
33. Ntoumanis N, Ng JY, Barkoukis V, Backhouse S. Personal and psychosocial predictors of doping use in physical activity settings: a meta-analysis. Sports Med. 2014;44(11):1603-24.
34. Ross R, Gray CM, Gill JM. Effects of an injected placebo on endurance running performance. Med Sci Sports Exerc. 2015;47(8):1672-81.
35. Saunders B, de Oliveira LF, da Silva RP et al. Placebo in sports nutrition: a proof-of-principle study involving caffeine supplementation. Scand J Med Sci Sports. In press.
36. Schimpchen J, Skorski S, Nopp S, Meyer T. Are "classical" tests of repeated-sprint ability in football externally valid? A new approach to determine in-game sprinting behaviour in elite football players. J Sports Sci. 2016;34(6):519-26.
37. Spencer M, Bishop D, Dawson B, Goodman C. Physiological and metabolic responses of repeated-sprint activities:specific to field-based team sports. Sports Med. 2005;35(12):1025-44.
38. Sullivan GM, Feinn R. Using effect size-or why the P value is not enough. J Grad Med Ed. 2012;4(3):279-82.
39. Trojian TH, Beedie CJ. Placebo effect and athletes. Curr Sports Med Rep. 2008;7(4):214-7.